Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial-论文-万方医学网

首页> > Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial

Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial

导出原文传递

翻译打印收藏纠错

第一作者： Roncero-ramos, Irene

作者： Roncero-ramos, Irene ^[1] ; Gutierrez-mariscal, Francisco M. ; Gomez-delgado, Francisco ; Villasanta-gonzalez, Alejandro ; Torres-pena, Jose D. ; de la Cruz-ares, Silvia ; Rangel-zuniga, Oriol A. ; Luque, Raul M. ; Ordovas, Jose M. ; Delgado-lista, Javier ; Perez-martinez, Pablo ; Camargo, Antonio ; Alcala-diaz, Juan F. ; Lopez-miranda, Jose

作者单位： Urol Sect,Univ Catania ^[1]

关键词 GLUCOSE-PRODUCTION CARDIOVASCULAR-DISEASE FAT ACCUMULATION GLYCEMIC CONTROL WEIGHT-LOSS SENSITIVITY PATHOPHYSIOLOGY DYSFUNCTION TOLERANCE SECRETION

发布时间 2022-04-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial

相似文献

同项目论文

相关期刊

检索历史 清除

Beta cell functionality and hepatic insulin resistance are major contributors to type 2 diabetes remission and starting pharmacological therapy: from CORDIOPREV randomized controlled trial

相似文献

同项目论文

相关期刊

检索历史清除